HomeArchive by category 'News' (Page 6)

News - News and Articles about commonly prescribed drugs

Fluoroquinolones Tied to Elevated Threat for Arrhythmia, CV Mortality

Posted in News on 31st October 2018
Results showed fluoroquinolone use increased the risk for arrhythmia by 85%

Results showed fluoroquinolone use increased the risk for arrhythmia by 85%

Fluoroquinolone antibiotics appear to increase the risk for arrhythmia and cardiovascular mortality, according to a study published in the journal Drug Safety.

To investigate the risk of cardiovascular adverse effects associated with this antibiotic class, researchers conducted a systematic review, meta-analysis, and network meta-analysis using studies identified through a search of MEDLINE, EMBASE, and the Cochrane Library; 13 studies were selected for inclusion. “Outcomes were pooled using random effects models,” the authors explained. “Direct and indirect comparisons in network meta-analysis were performed using frequentist methods.”

Results showed fluoroquinolone use increased the risk for arrhythmia by 85% (odds ratio [OR] 1.85; 95% CI, 1.22–2.81) and cardiovascular mortality by 71% (OR 1.71; 95% CI, 1.39–2.09). Of the fluoroquinolones included in the analysis, moxifloxacin was found have the highest probability for cardiovascular adverse events (arrhythmia [P-score 0.99]; cardiovascular mortality [P-score 0.95]).

“Our findings show a significant association between fluoroquinolone use and an increased risk for arrhythmia and cardiovascular mortality,” the authors concluded. They added, “Further study is required to determine how to reduce the risk for fluoroquinolone-associated cardiac toxicity.”

Investigational drug focusing on the opioid system might assist scale back signs of main melancholy

Posted in News on 30th October 2018

Two medical trials of an investigational drug that targets the opioid system help its security and effectiveness in lowering signs of main melancholy, when added to straightforward antidepressant therapy. The outcomes of those Part three trials of a drug combining buprenorphine with samidorphan are reported immediately in Molecular Psychiatry by a analysis workforce led by a Massachusetts Basic Hospital doctor.

“Lower than 40 p.c of sufferers with main melancholy obtain symptom remission from first-line therapy with immediately’s antidepressant medicine, which goal monoamine-based neural signaling,” explains Maurizio Fava, MD govt director of the Medical Trials Community & Institute within the MGH Division of Psychiatry and senior creator of the Molecular Psychiatry report. “Having a brand new class of antidepressants with a novel mechanism of motion may have vital affect for sufferers with persistent signs.” Fava additionally led the Part 2 trial of this drug mixture, which was revealed in 2016 and recognized the effectiveness of the best dosage degree examined within the present trials.

The endogenous opioid system – the neurological pathways that work together with opioid medicine – is believed to have a job in a number of elements that may be affected in medical melancholy – together with temper, motivation and social features. PET imaging research have steered that opioid system circuits could also be dysregulated in sufferers with main melancholy. Whereas low doses of buprenorphine – an opioid used for each ache aid and in medication-assisted therapy for opioid dependancy – had helpful results in a multicenter trial in sufferers with main melancholy, a significant problem to its use for melancholy therapy is the danger of abuse and dependence.

The mix of buprenorphine with samidorphan, which blocks one of many opioid receptors activated by buprenorphine, was designed to scale back the abuse and dependence potential of buprenorphine alone. The drug – additionally known as ALKS 5461 – is being developed by Alkermes, Inc., which sponsored the 2 trials, known as FORWARD-Four and FORWARD-5, performed at a complete of 111 websites in a number of international locations. FORWARD-Four in contrast two dosage ranges – both zero.5 mg of every drug or 2.zero mg of every – with a placebo; and FORWARD-5 in contrast 1.zero mg and a pair of.zero mg doses with a placebo. A complete of just about 800 grownup sufferers who had not responded adequately to at the very least eight weeks of antidepressant therapy enrolled and continued taking their customary antidepressant all through the trial interval.

Since trials of melancholy medicine typically elicit a big placebo impact, each trials have been designed in a strategy to scale back that danger. In the course of the first stage of each randomized trials, individuals acquired their assigned doses of both the energetic drug or a placebo for five weeks, on the finish of which they accomplished a normal melancholy symptom evaluation. Though neither individuals nor the analysis workforce members with whom they immediately interacted knew particular person sufferers’ group assignments, different workforce members examined assessments from these receiving a placebo, figuring out these in whom symptom discount indicated a placebo impact.

Placebo group members who didn’t present symptom enchancment have been re-randomized both to proceed receiving the placebo or to obtain one of many examined doses of the energetic drug for the remaining 6 weeks of the trial. Once more, they weren’t conscious that their examine remedy had been modified. Different individuals – each these receiving an energetic drug and people who have been responding to the placebo – continued with the identical remedy throughout the second part.

On the finish of each trials, individuals receiving the two.zero mg doses of each energetic medicine had a larger discount in melancholy signs than did these receiving a placebo. These receiving 1.zero mg doses confirmed symptom discount larger than the placebo group however lower than the two.zero mg doses, and the zero.5 mg-dose recipients had outcomes no higher than these of the placebo group. Though the variations between the two.zero mg dosages and placebo in FORWARD-Four weren’t statistically vital, combining the outcomes from each trials produced a big impact.

Reported adversarial results – similar to nausea, sleepiness, dizziness and fatigue – have been gentle to reasonable and normally disappeared inside a number of days. There have been no stories of individuals’ taking extra doses, creating dependence or experiencing withdrawal signs. After their trial, individuals have been in a position to enroll in a long-term security examine of mixed buprenorphine/samidorphan. Interim knowledge from that examine have been introduced on the American Psychiatric Affiliation annual assembly in Could 2018.

“Based mostly on the protection profile noticed with buprenorphine/samidorphan, we may have an necessary new pharmacological software for sufferers with main melancholy who don’t reply to straightforward therapies,” says Fava, the Slater Household Professor of Psychiatry at Harvard Medical College.



Generally Prescribed Antihypertensives Linked to Elevated Lung Most cancers Threat

Posted in News on 30th October 2018

October 29, 2018

Concerns of cancer risk associated with this antihypertensive class have been a subject of debate

Concerns of cancer risk associated with this antihypertensive class have been a subject of debate

Long-term use of angiotensin-converting enzyme inhibitors (ACEIs) may increase the risk of lung cancer, according to a study published in the BMJ.

To investigate the association between this commonly used antihypertensive class and lung cancer, researchers conducted a population based cohort study involving 992,061 patients from the United Kingdom Clinical Practice Research Datalink. Between January 1 1995 and December 31 2015, they identified patients newly treated with an antihypertensive medication and followed them until December 31 2016. “Cox proportional hazards models were used to estimate adjusted hazard ratios (HR) with 95% confidence intervals (CI) of incident lung cancer associated with the time varying use of ACEIs, compared with use of angiotensin receptor blockers (ARBs), overall, by cumulative duration of use, and by time since initiation,” the authors explained.

Related Articles

The study cohort was followed for a mean of 6.4 years; during this time, 335,135 patients were treated with ACEIs, with the 3 most commonly prescribed drugs being ramipril, lisinopril, and perindopril. During 6,350,584 person years of follow-up, 7952 patients were newly diagnosed with lung cancer (crude incidence rate: 1.3 per 1000 person years). Data showed that compared with ARBs, the use of ACEIs was associated with a 14% increased risk of lung cancer (incidence rate: 1.6 vs 1.2 per 1000 person years; HR 1.14, 95% CI, 1.01 to 1.29). While the use of ACEIs for <5 years was not associated with increased risk, hazard ratios increased with longer duration of ACEI use (5-10 years: HR 1.22; >10 years: HR 1.31).

“The magnitudes of the observed estimates are modest, but these small relative effects could translate into large absolute numbers of patients at risk, so these findings should be replicated in other settings,” the authors concluded.

For more information visit BMJ.com.

Scroll down to see the next article

The Lancet Infectious Ailments journal publishes medical trial outcomes for Shionogi’s cefiderocol

Posted in News on 29th October 2018

Shionogi & Co., Ltd. (hereafter “Shionogi”) introduced right this moment that The Lancet Infectious Ailments journal has printed medical outcomes from the pivotal randomized managed trial evaluating cefiderocol for the therapy of sophisticated urinary tract an infection (cUTI) in sufferers liable to multidrug-resistant Gram-negative infections.

The paper is titled “Cefiderocol versus imipenem-cilastatin for the therapy of sophisticated urinary tract infections attributable to Gram-negative pathogens: a section 2, randomized, double-blind, non-inferiority trial.”

Outcomes from the examine demonstrated therapy with cefiderocol met non-inferiority versus imipenem/cilastatin (IPM/CS) in sufferers with cUTI at check of remedy (TOC). Within the examine, 73 p.c (183/252) of sufferers within the cefiderocol group met the first endpoint (mixture of medical response and microbiological response at TOC) versus 55 p.c (65/119) within the IPM/CS group, with an adjusted therapy distinction of 18.58 p.c. These leads to a post-hoc evaluation confirmed that cefiderocol was superior to IPM/CS. The examine enrolled 452 sufferers with cUTI and sufferers had been randomly assigned 2:1 to cefiderocol and IPM/CS with a median length of therapy of 9 days for each teams.

The microbiologic response price at TOC for the cefiderocol group was 73 p.c (184/252) versus 56 p.c (67/119) within the IPM/CS group, with the distinction between teams at TOC at 17.25 p.c. Though the examine was designed to find out non-inferiority, the findings confirmed that cefiderocol resulted in a clinically significant microbiological eradication charges and outperformed IPM/CS. Moreover, cefiderocol exhibited a security profile per that of different cephalosporins.

“The info offered in The Lancet Infectious Ailments reveals the potential of cefiderocol, notably in an advanced affected person inhabitants with comorbidities and at larger danger of multidrug-resistant an infection with tough to deal with Gram-negative micro organism,” mentioned Dr. Tsutae “Den” Nagata, Chief Medical Officer, Shionogi & Co. Ltd. “As soon as authorised, cefiderocol might be an necessary, new antibiotic possibility for suppliers caring for these very sick sufferers who might have very restricted therapy choices.”


Expiration Dates Prolonged for Sure A lot of Generic Adrenaclick

Posted in News on 29th October 2018
Expiration date for specific lots will be increased from 18 months to 20 months

Expiration date for specific lots will be increased from 18 months to 20 months

The expiration dates for certain lots of epinephrine injection, USP auto-injector 0.15mg and 0.3mg (Impax Laboratories), the authorized generic of Adrenaclick, have been extended by 2 months after the Company coordinated with the Food and Drug Administration (FDA) to address the ongoing drug shortage.

Epinephrine auto-injectors are indicated for the emergency treatment of allergic reactions (Type 1) including anaphylaxis. The expiration dates of these lots have been increased from 18 months to 20 months; the full list can be viewed here.  “This announcement is made after a comprehensive evaluation of data to enable the extension of the expiration date on specific lots,” said Joseph Greer, SVP, Global Quality Management, in a press release. 

Page 6 of 104:« 1 2 3 4 5 6 7 8 9 10 11 » Last »